# Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase

> **NCT05143840** · PHASE2 · RECRUITING · sponsor: **Augusta University** · enrollment: 100 (estimated)

## Conditions studied

- Chronic Myeloid Leukemia, Chronic Phase
- Adult CML
- Leukemia, Myeloid
- Leukemia,Myeloid, Chronic

## Interventions

- **DRUG:** Single Agent Asciminib
- **COMBINATION_PRODUCT:** Low TKI
- **OTHER:** Elective Free Treatment

## Key facts

- **NCT ID:** NCT05143840
- **Lead sponsor:** Augusta University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-04-22
- **Primary completion:** 2032-02
- **Final completion:** 2032-02
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05143840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05143840, "Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05143840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*